toviaz 4 mg
farmagon - fesoterodinfumarat - depottablett - 4 mg
toviaz 8 mg
farmagon - fesoterodinfumarat - depottablett - 8 mg
fesoterodine zentiva 4 mg
zentiva k.s. - fesoterodinfumarat - depottablett - 4 mg
fesoterodine zentiva 8 mg
zentiva k.s. - fesoterodinfumarat - depottablett - 8 mg
metformin zentiva 1000 mg
zentiva k.s. - metforminhydroklorid - tablett, filmdrasjert - 1000 mg
metformin zentiva 500 mg
zentiva k.s. - metforminhydroklorid - tablett, filmdrasjert - 500 mg
metformin zentiva 850 mg
zentiva k.s. - metforminhydroklorid - tablett, filmdrasjert - 850 mg
adempas
bayer ag - riociguat - hypertensjon, pulmonal - antihypertensive midler for pulmonal arteriell hypertensjon - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har vært vist i en pah befolkningen, herunder aetiologies av idiopatisk eller heritable pah eller pah assosiert med bindevev sykdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
revasc
canyon pharmaceuticals ltd. - desirudin - venøs trombose - antithrombotic agents - forebygging av dyp venøs trombose hos pasienter som gjennomgår valgfri hofte- eller kneutskifting.
volibris
glaxosmithkline (ireland) limited - ambrisentan - hypertensjon, pulmonal - antihypertensiva, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.